Meta Title: Merck & Co Inc Patent Granted for Tricyclic Heterocycle Compounds for Treating HIV

According to GlobalData’s company profile on Merck, Human telomerase RT biomarker was a key innovation area identified from patents. Merck‘s grant share as of January 2024 was 54%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11884683B2) discloses a compound of a specific formula with various substituents, including halo groups and pharmaceutically acceptable salts. The patent claims cover different configurations of the compound, allowing for flexibility in the development of pharmaceutical compositions. These compositions include the compound in combination with a pharmaceutically acceptable carrier for effective delivery.

Moreover, the patent claims encompass methods for inhibiting HIV integrase and treating HIV infection or AIDS by administering the disclosed compound or its salts to individuals in need. The patent also includes the option of combining the compound with other therapeutic agents like raltegravir, lamivudine, and ritonavir to enhance treatment efficacy. This comprehensive approach aims to provide a versatile and potent solution for combating HIV infection and managing AIDS, highlighting the potential impact of this patented compound in the field of antiretroviral therapy.

To know more about GlobalData’s detailed insights on Merck, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies